Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química
Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical
Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by
measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation
demonstrated by transvaginal ultrasound examinations
Phase:
Phase 3
Details
Lead Sponsor:
Azidus Brasil
Collaborators:
União Química Farmacêutica Nacional S.A. União Química Farmacêutica Nacional S/A